Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
The report asserts that without continued and consistent US investment in global health research - which has so far “helped deliver some of the greatest advances the field has ever seen” - the momentum needed to do drive these advances “over the finish line” will be compromised.
The report will be released at a congressional briefing at noon, Tuesday, February 26, at the Russell Senate Office Building, Washington, DC. An expert panel - including Dr Caroline Ryan, Director of Technical Leadership, Office of the Global AIDS Coordinator, Department of State, PEPFAR (President’s Emergency Plan for AIDS Relief) and Dr Alan Magill, Director of Malaria, Bill & Melinda Gates Foundation - will be speaking at the event.
For more information, contact Katy Lenard (klenard@burnesscommunications.com)
T: +1 301-280-5719
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.